通过使用药理平衡建模的GluN2A选择性对抗剂对全性N-甲基-d-酸盐受体调节的评估
James S Lotti1, Jaron Jones1, Jill C Farnsworth1
1Center for Structural and Functional Neuroscience, Center for Biomolecular Structure and Dynamics, Division of Biological Sciences, University of Montana, Missoula, Montana.
Molecular pharmacology
|February 7, 2025
概括
一个新的模型量化了N-甲基-d-酸盐 (NMDA) 受体全调节剂,揭示了结合亲和力和疗效的差异. 这有助于开发针对大脑疾病的向疗法,通过了解连接体-受体相互作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- N-甲基-d-酸盐 (NMDA) 受体对大脑功能至关重要,并与神经系统疾病有关.
- 基调节剂为NMDA受体功能障碍提供治疗潜力.
- 现有的模型缺乏精度,无法完全描述这些调节器的结合和效应.
研究的目的:
- 开发和应用NMDA受体激活和全调节的药理平衡模型.
- 量化评估GluN2A选择性负基调节剂 (TCN-201,MPX-004,MPX-007) 的使用情况.
- 了解调节器特性如何影响它们的治疗效用,并指导未来的药物设计.
主要方法:
- 为NMDA受体功能开发了一种通用的联体受体平衡模型.
- 利用半平衡条件与缓慢的负调节器解结.
- 在GluN1/2A和GluN1/2A/2B受体上应用该模型来表征TCN-201,MPX-004和MPX-007.
主要成果:
- 对TCN-201,MPX-004和MPX-007.7的量化结合解离常数 (KB) 和激素结合亲和度调制 (α).
- 证明对激动剂有效性 (β) 的差异性影响,MPX-004增加了它,TCN-201/MPX-007降低了它.
- 在二异体和三异体NMDA受体亚型中观察到一致的调制特征.
结论:
- 开发的模型为评估NMDA受体全调节器提供了一个强大的框架.
- 描述了TCN-201,MPX-004和MPX-007的独特药理学概况,以告知它们作为研究工具的使用.
- 这些发现有助于解释结构-活性关系,并设计针对NMDA受体的新型治疗方法.
相关概念视频
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Allosteric Regulation
57.5K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.5K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K
Cooperative Allosteric Transitions
7.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.8K
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Drug-Receptor Interactions
4.8K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.8K


